Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406904 | 0.89 | HPGD (0.35) | NPSR1HPGDGFERHSD17B10ALDH1A1 | |
| SCHEMBL20891233 | 0.82 | HPGD (0.38) | NPSR1HPGDGFERHSD17B10ALDH1A1 | |
| SCHEMBL24253344 | 0.81 | KDM4E (0.44) | NPSR1HPGDGFERHSD17B10ALDH1A1 | |
| SCHEMBL22993438 | 0.80 | SLC6A2 (0.40) | ALDH1A1CYP2D6KDM4EMAPT | |
| SCHEMBL26956228 | 0.79 | BRD4 (0.41) | MEN1KMT2AKDM4E | |
| SCHEMBL20704273 | 0.79 | SLC6A2 (0.37) | HTR2AHTR2C | |
| SCHEMBL29516105 | 0.79 | BRD4 (0.41) | MEN1KMT2AKDM4E | |
| SCHEMBL30561505 | 0.79 | SLC6A2 (0.37) | HTR2AHTR2C | |
| SCHEMBL26792092 | 0.78 | HPGD (0.41) | NPSR1HPGDGFERHSD17B10ALDH1A1 | |
| SCHEMBL25691515 | 0.77 | GABRA1 (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | NPSR1 891/4885HPGD 506/4885GFER 1165/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | NPSR1 891/4885HPGD 506/4885GFER 1165/4885 |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | NPSR1 3227/4885HPGD 1844/4885GFER 4642/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | NPSR1 891/4885HPGD 506/4885GFER 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.